ArticleFrontiers in cell and developmental biology2026
Extending the residence period of allogeneic iPSC-derived invariant natural killer T cells in humanized mice by editing HLA class I expression.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cell (iPSC)-derived immune cells show promise for allogeneic immunotherapies. However, their clinical efficacy can be limited by early rejection of grafted iPSC-derived cells by host T cells and natural killer (NK) cells due to HLA mismatching. In theory, disrupting HLA class I expression can prevent T cell-mediated rejection, but, in its place, NK cells can eliminate "missing-self" targets due to the absence of HLA-C and HLA-E. Therefore, we devised a strategy to extend the residence time of iPSC-derived invariant natural killer T (iPSC-derived iNKT) cells in humanized mice harboring allogeneic peripheral blood mononuclear cells (PBMCs) by genetically modifying HLA class I expression. To this end, we disrupted HLA class I expression by deleting the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.